CA-MFA
16.11.2021 15:03:14 CET | Business Wire | Press release
MFA , an international organization championing the global industry adoption of private networks based upon 3GPP technologies, today announced its Network Identifier Program for enterprises. Enterprises now have access to the MFA’s unique global PLMN ID that they can use when deploying their own private network to ensure that only authorized devices connect to their network. The program reduces complexity and streamlines the network development process for enterprises by eliminating the need for them to separately apply for their own PLMN ID.
“Our mission is to make it as easy as possible for enterprises to quickly deploy their own private network and realize the benefits of greater control over their network, enhanced on-premise data security, and predictable performance,” said Mazen Chmaytelli, president, MFA. “MFA was awarded a unique global PLMN ID by the ITU, and we are creating this new program to ensure all industry verticals have ready access to a PLMN ID that will support their digitalization journey.”
Enterprises and industry verticals including maritime, manufacturing, warehouses, utilities, and venues can select a Private Network ID package or a Neutral Host Network (NHN) ID package that will provide them with all the items they need to deploy a neutral host or private network. For large deployments, enterprises will be able to add-on IDs to meet their requirements for coverage and capacity.
“With access to the global PLMN ID from MFA, network suppliers or operators will have the necessary identifiers to create unique and distinguishable private networks, streamlining the deployment process for their enterprise customers – anywhere in the world they are located,” said Asimakis Kokkos, MFA Technical Specification Group Chair and Head of Technology Ecosystems, Nokia Enterprise Solutions.
New Private Network Subscriber category created to jumpstart deployment
MFA has also created a new Private Network Subscriber
category that will grant enterprises one complimentary Private Network ID package that they can use immediately to deploy their own 5G private network in locally licensed spectrum or MulteFire®/4G private network in unlicensed spectrum today.
“For a one-time fee, Private Network Subscribers gain access to a Private Network ID package that is evergreen and does not need to be renewed,” added Chmaytelli. “Our members also will receive complimentary packages that will meet their deployment requirements. The MFA wants to help seed as many private networks as possible, and we’re excited to bring this important program to the entire industry.”
To further enable private network deployments, MFA, a 3GPP Market Representation Partner (MRP), previously announced that it is also developing Uni5G™ Technology Blueprints. These blueprints will provide enterprises with practical guidance on implementing the key features from the 3GPP 5G standards that are relevant to their specific deployment. The first blueprints will be finalized in December 2021.
The Network Identifier program is administered by the MFA Certificate Authority and is available today to MFA members and non-members. For companies interested in joining the program, visit www.mfa-tech.org .
Resources:
- White Paper: “5G Private Networks for Maritime Use: Opportunities for Digital Port Automation ,” Beecham Research
- White Paper: "The Importance of Spectrum Liberalization for Private 5G Networks ," ABI Research
- Video: Uni5G and MulteFire Private Networks for Manufacturing
About MFA
MFA is an international organization that is championing the global industry adoption of private networks using MFA-defined MulteFire specifications for LTE and Uni5G Technology Blueprints for 5G. With Uni5G or MulteFire, enterprises can efficiently deploy their own optimized, reliable and secure private network in unlicensed, shared or locally licensed spectrum. For more information, visit www.mfa-tech.org
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005294/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
